Premium
Prescribing practices of migraine‐specific pharmacotherapy associated with emergency department use for migraine
Author(s) -
Cheng Vivian,
Billups Sarah J.,
Saseen Joseph J.
Publication year - 2021
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/head.14029
Subject(s) - medicine , migraine , emergency department , medical prescription , neurology , retrospective cohort study , cohort , migraine treatment , cohort study , triptans , emergency medicine , pediatrics , psychiatry , pharmacology
Objective This study compared migraine medication prescribing between patients with a migraine diagnosis who used versus did not use the emergency department (ED) for migraine. Background Headache is the fifth most common chief complaint for ED visits nationwide and the third most common potentially avoidable ED diagnosis in the University of Colorado Health system. The reasons some patients use the ED for migraine management while others do not and whether some ED admissions might be preventable remain unclear. Methods This retrospective cohort study identified adults with migraine‐related diagnoses within 1 year before the index date of July 1, 2018 and compared patient characteristics and migraine medication prescribing patterns between those who did or did not have a subsequent migraine‐related ED encounter the following year. ED admission notes were manually reviewed to identify potentially preventable circumstances that led to the ED visit. The primary outcome was the proportion of patients with an active triptan prescription at the index date. Results Of the 3843 patients identified, 35 patients (0.9%) had a migraine‐related ED encounter. Of these, 17/35 (49%) had an active triptan prescription compared to 1360/3808 (36%) of non‐ED utilizers ( p = 0.114), OR 1.22 (95% CI 0.61–2.45). More ED utilizers had an active prescription for opioids (11/35 [31%] vs. 663/3808 [17%], p = 0.030) and migraine preventive therapy (19/35 [54%] vs. 1149/3808 [30%], p = 0.002), and neurology referrals (20/35 [57%] vs. 654/3808 [17%], p < 0.001) compared to non‐ED utilizers. The most common circumstance for migraine‐related ED visits was nonresponse to migraine abortive medications administered at home. Conclusions Triptan prescribing did not differ between ED utilizers and non‐ED utilizers for migraine. Overall, less than half of the total patient population had a triptan prescribed. More ED utilizers had neurology referrals, prescriptions for opioids and preventive therapies, and a history of previous ED visit for any reason, which may be markers for higher disease severity or behavior patterns. Future research and interventions to reduce migraine‐related ED use could target high‐risk patients such as those with previous ED visits for any indication and neurology referrals.